<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        31-29-83
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1983
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PREGNYL +SOLVENT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CHORIOGONADOTROPIN ALFA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        41.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ORGANON" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ORGANON
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ORGANON
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03GA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pregnyl contains the hormone known as human chorionic gonadotropin (hCG), which belongs to a group of medicines called gonadotropins. These are important for fertility and reproduction.</p><p>&nbsp;</p><p>Pregnyl is obtained from the urine of pregnant women. HCG has the same effect on the body as luteinising hormone (LH), which is produced in the pituitary gland of men and women. The pituitary is a small hormone-producing gland located at the base of the brain. Together with another pituitary hormone, follicle-stimulating hormone (FSH), LH regulates the function of the reproductive organs (ovaries in women and testicles in men). These hormones are necessary for the normal growth and ripening of egg and sperm cells.</p><p>&nbsp;</p><p style="margin-left:0in"><strong>In </strong><strong>women</strong></p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->In women, FSH and LH cause the monthly ripening of an egg cell in one of the ovaries. LH is also needed for ovulation: the release of the egg cell. If the body does not produce enough FSH and LH on its own, this can lead to low fertility. Daily injections of FSH can lead to ripening of the egg cell. Pregnyl ensures that ovulation takes place afterwards.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Pregnyl can also be given in assisted reproductive techniques, both before and after ovulation.</p><p>&nbsp;</p><p style="margin-left:0in"><strong>In </strong><strong>men</strong></p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->In men, Pregnyl can be used on its own or together with an FSH-containing product, when there is underdevelopment of the sex glands or when there are problems with the formation of sperm.</p><p>&nbsp;</p><p><strong>In boys</strong></p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->In boys, Pregnyl can be used for delayed puberty, on its own or together with an FSH-containing product.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->In some cases Pregnyl can also be given to boys in whom one or both testicles has not descended.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in"><strong>Do not </strong><strong>use Pregnyl</strong></p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are allergic (hypersensitive) to any of the ingredients in this medicine (listed in section&nbsp;6).</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have a known or suspected sex hormone-dependent tumour in the ovaries, breast, uterus, prostate, testicles or brain (pituitary or hypothalamus).</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if your reproductive glands (ovaries or testicles) are not working, due to so-called &lsquo;gonadal failure&rsquo;.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are a woman and you have malformations of the sex organs that make pregnancy impossible.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are a woman and you have uterine fibroids (myomas), which make pregnancy impossible.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are a woman and you have unexplained heavy or irregular vaginal bleeding.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are a woman and you have ovarian cysts or enlarged ovaries, not related to Polycystic Ovary Syndrome (PCOS, a condition in which the egg cells do not ripen and no ovulation takes place).</p><p>&nbsp;</p><p style="margin-left:0in"><strong>Warnings </strong><strong>and precautions</strong></p><p>Talk to your doctor or pharmacist before using this medicine.</p><p>&nbsp;</p><p><em>For men and women</em></p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->The presence of untreated non-gonadal (having no involvement with the reproductive glands) endocrine (hormonal) abnormalities (such as diseases of the thyroid, adrenal gland or pituitary gland) must be ruled out.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->Pregnyl must not be used for weight loss. HCG has no effect on fat metabolism (burning fat), distribution of fat or appetite.</p><p>&nbsp;</p><p><em>If you are a woman</em></p><p>Close supervision by your doctor is very important.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->If treatment with gonadotropins results in a pregnancy, there is an increased risk of having twins or multiple births.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->The risk of an ectopic pregnancy is slightly higher in women with damaged fallopian tubes.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->In women undergoing fertility treatment there may be a slightly higher risk of miscarriage.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->Multiple pregnancies and characteristics of the patients undergoing fertility treatment (e.g. the woman&rsquo;s age, sperm characteristics) may carry an increased risk of congenital malformations. There is no evidence that the use of gonadotropins itself increases the risk of congenital malformations.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->Usually ultrasound scans of the ovaries are made regularly and blood samples are taken regularly. The results of these tests allow your doctor to choose the correct daily dose of FSH. This is very important, since too high a dose of gonadotropins may lead to rare complications in which the ovaries become overstimulated. This may be noticed as pain in the abdomen, with nausea or diarrhoea, painful breasts, and temporarily abnormal values in liver function tests. In rare cases, a severe form of ovarian hyperstimulation syndrome develops, which can be life-threatening. This warning is particularly important for patients with Polycystic Ovary Syndrome (PCOS). Regular monitoring of the response to gonadotropin treatment helps your doctor to prevent this unwanted overstimulation.<br />You must notify your doctor immediately if you have abdominal pain.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->Treatment with Pregnyl (like pregnancy itself) may lead to a slightly higher risk of thrombosis (the formation of a blood clot in a blood vessel, most often in the veins of the legs or the lungs). Discuss this with your doctor before starting treatment, especially if:</p><p style="margin-left:28.35pt; margin-right:0in; text-align:justify; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you already know you have an increased risk of thrombosis</p><p style="margin-left:28.35pt; margin-right:0in; text-align:justify; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you, or anyone in your immediate family, have ever had a thrombosis</p><p style="margin-left:28.35pt; margin-right:0in; text-align:justify; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you are severely overweight.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->For up to 10&nbsp;days after administration of Pregnyl, a pregnancy test may give a false-positive result.</p><p>&nbsp;</p><p><em>If you are a man</em></p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->Treatment with hCG can lead to the production of antibodies to hCG (these are proteins that counteract the effect of hCG). In rare cases this could result in ineffective treatment.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->Treatment with hCG leads to increased production of androgens (male sex hormones). Therefore, extra supervision by the doctor is necessary if you have or have ever had:</p><p style="margin-left:28.35pt; margin-right:0in; text-align:justify; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->cardiovascular disease</p><p style="margin-left:28.35pt; margin-right:0in; text-align:justify; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->kidney disease</p><p style="margin-left:28.35pt; margin-right:0in; text-align:justify; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->high blood pressure</p><p style="margin-left:28.35pt; margin-right:0in; text-align:justify; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->epilepsy</p><p style="margin-left:28.35pt; margin-right:0in; text-align:justify; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->migraines</p><p style="margin-left:14.2pt; margin-right:0in">because the increased production of androgens may in some cases lead to worsening or recurrence of these conditions.</p><p>&nbsp;</p><p style="margin-left:0in"><strong>Children and adolescents up to the age of 18 years </strong></p><p>Extra supervision by a doctor is necessary when treating boys who have not yet reached puberty. This is because Pregnyl can induce early sexual development and may slow growth.</p><p>&nbsp;</p><p style="margin-left:0in"><strong>Other </strong><strong>medicines and Pregnyl</strong></p><p>The effects of Pregnyl on other medicines has not been studied; interactions with commonly used medicines can therefore not be ruled out.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p style="margin-left:0in"><strong>Pregnancy and </strong><strong>breast-feeding</strong></p><p>You must not use Pregnyl during pregnancy. Pregnyl may be used to support a (possible) pregnancy during the period just after ovulation (luteal phase).</p><p>If you are breast-feeding, ask your doctor for advice before taking this medicine. Use of Pregnyl can be considered while nursing a baby.</p><p>&nbsp;</p><p style="margin-left:0in"><strong>Driving and using machines</strong></p><p>As far as is known, Pregnyl has no effect on the ability to drive or operate machines.</p><p>&nbsp;</p><p style="margin-left:0in"><strong>Pregnyl contains sodium</strong></p><p>This medicine contains less than 1 mmol of sodium (23 mg) per injection, i.e. essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in"><strong>Dosage</strong></p><p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will decide on the dose of Pregnyl to be given and will supervise your first injection.</p><p>&nbsp;</p><p>In <strong>female patients</strong> one injection is usually given to induce ovulation and up to 3 injections to support the luteal phase that follows.</p><p>In <strong>male patients</strong> (men and boys) the injections are given 2 or 3 times a week. The treatment will last from a few weeks to at least 3 months, depending on the problem being treated. The length of treatment depends on the time needed for development of sperm and the period in which an improvement can be expected.</p><p>&nbsp;</p><p style="margin-left:0in"><strong>How the </strong><strong>injections are given </strong></p><p>The powder for injection must be dissolved with the<strong> </strong>liquid<strong> </strong>from the other ampoule (the solvent). This solution must be used immediately after that. The Pregnyl solution can be injected slowly into muscles (for instance, in the buttock, upper leg or upper arm) or just under the skin (for instance, in the lower abdomen). When injecting into a muscle, the injection must be given by the doctor or nurse. When given under the skin, injections may, in some cases, be given by yourself or your partner. Your doctor will tell you when and how to do this. If you are injecting yourself with Pregnyl, follow the instructions in the next section, so that you administer Pregnyl properly and with minimal discomfort from the injection.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p style="margin-left:0in"><strong>Instructions for use</strong></p><p><em>Step 1 &ndash; </em><em>Preparing</em><em> the injection syringe</em></p><p>The dry material in the glass ampoule must be dissolved in the solvent from the other glass ampoule. To do so, first break the top off the ampoule with the solvent (Figure a), keeping the black spot in the position shown in Figures a and c. Hold a piece of gauze between the ampoule and your fingers to avoid cutting yourself on the broken edge of the glass. Draw the solvent up through the needle into the syringe (Figure b). Then break the top off the ampoule with the dry material (Figure c). Inject the solvent into the ampoule with the dry material (Figure d). DO NOT SHAKE, but swirl gently until the solution is clear. Pregnyl usually dissolves immediately. The prepared solution should not be used if it contains particles or is cloudy. Make sure that everything is carried out so that during reconstitution sterile conditions are maintained (e.g., never put the syringe down without first putting the protective cap on the needle). Draw the Pregnyl solution up into the empty syringe (Figure e), and replace the needle used for drawing up the solution with a sterile injection needle (Figure f). Hold the syringe with the needle pointing upwards and gently tap the side to allow any air bubbles to rise to the top. Then, push the plunger until all the air is out of the syringe and only Pregnyl solution is present in the syringe (Figure g).</p><p>&nbsp; &nbsp; &nbsp; &nbsp;</p><p><!--[if !mso]--></p><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p><strong>UNDER THE SKIN</strong></p><!--[if !mso]--></td></tr></tbody></table><p><!--[endif]--><em>&nbsp;</em><em> </em><em>&nbsp;</em><em> </em><em>&nbsp;</em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Step 2 &ndash; </em><em>The</em><em> injection site</em></p><p>The best injection site for subcutaneous injection is in the abdomen around the navel (Figure h), where there is a lot of loose skin and layers of fatty tissue. Other injection sites are also possible. Choose a slightly different place for each injection. Your doctor or nurse will tell you where to inject.</p><p>&nbsp;</p><p><em>Step 3 -</em><em> Preparing the injection site</em></p><p>Tap a few times on the injection site to stimulate tiny nerve endings. This reduces the pain when the needle goes into the subcutaneous tissue. Wash your hands and clean the injection site with a swab containing an antiseptic (for example chlorhexidine 0.5%) to remove any surface bacteria. Clean an area of about five centimetres (two inches) around the injection site and let the antiseptic dry for at least one minute before you go on to the next step.</p><p>&nbsp;</p><p><em>Step</em><em> 4 - Inserting the needle </em></p><p>Grasp a fold of skin between thumb and forefinger. With the other hand, stick the needle into the fold of skin at a 45-degree angle, as shown in Figure i.</p><p>&nbsp;</p><p><em>Step 5 -</em><em> Checking the correct needle position</em></p><p>Pull the plunger of the syringe back gently, to check that the needle is in the correct position. If blood is drawn into the syringe, it means a vein has been punctured. If this happens, remove the needle from the skin and apply pressure on the injection site with a swab containing an antiseptic; bleeding should stop after about two minutes. Do not use the solution contaminated with blood. <strong><em>Start again from</em></strong><strong><em> step 1</em></strong> using a new syringe, new needles, and new ampoules of Pregnyl and solvent.</p><p>&nbsp;</p><p><em>Step 6</em><em> - </em><em>Injecting</em><em> the</em><em> solution</em></p><p>Depress the plunger <strong>slowly</strong> and steadily. This way the solution will be injected properly without injuring the muscle or subcutaneous tissue.</p><p>&nbsp;</p><p><em>Step 7 -</em><em> Removing the syringe</em></p><p>With a quick movement, pull the needle out of the skin and apply pressure on the injection site with a swab containing an antiseptic. Gently massaging the skin &ndash; while you are still applying pressure &ndash; helps disperse the Pregnyl solution more easily and reduces the pain. Any remaining solution should be discarded. Do not mix Pregnyl with any other medicines.</p><p>&nbsp;</p><p><em>Step 8 &ndash;</em><em> Disposing the needles</em></p><p>Put the syringe back into the protective sheath to prevent injury.</p><p>Carefully dispose of all the needles you used. You can either dispose of needles in a sharps bin or take them to your pharmacy to be destroyed. Do not share your needles or syringes with others.</p><p><strong>&nbsp;</strong></p><p style="margin-left:0in"><strong>If you </strong><strong>use more Pregnyl than you should</strong></p><p>If you used too much Pregnyl, contact your doctor or pharmacist immediately.</p><p>The toxicity of Pregnyl is very low, but a dose of Pregnyl that is too high can cause ovarian hyperstimulation syndrome (see also section&nbsp;2, &lsquo;Warnings and precautions&rsquo; and section&nbsp;4 on &lsquo;Possible side effects&rsquo;).</p><p>&nbsp;</p><p style="margin-left:0in"><strong>If you </strong><strong>forget to use Pregnyl</strong></p><p>Never take a double dose to make up for a forgotten dose.</p><p>Tell your doctor that you missed a dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Most of these reactions are of a mild nature and go away on their own.</p><p style="text-align:justify">Common side effects occur in less than 1 in 10 patients.</p><p style="text-align:justify">Uncommon side effects occur in less than 1 in 100 patients.</p><p style="text-align:justify">Rare side effects occur in less than 1 in 1000 patients.</p><p>&nbsp;</p><p>Pregnyl can cause bruising, pain, redness, swelling and itching at the site of injection. Allergic reactions are rare, and mostly involve pain or rash at the injection site.</p><p>In rare cases generalized hypersensitivity can occur, such as a rash on several areas of the body, or fever.</p><p>&nbsp;</p><p style="margin-left:0in"><strong>If you are a woman</strong></p><p>If your ovaries have been stimulated by an FSH-containing preparation and Pregnyl is given, it may lead to unwanted overstimulation of the ovaries. Mild overstimulation is common, and may be felt as:</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->pain in the abdomen or stomach, with nausea, diarrhoea or a bloated sensation.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->painful breasts</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->mild to moderate enlargement of the ovaries</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->ovarian cysts.</p><p>&nbsp;</p><p>Severe overstimulation is rare; it may be accompanied by:</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->large ovarian cysts</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden abdominal pain</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->fluid retention in the chest and abdominal cavities (ascites and hydrothorax)</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->weight gain</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->(rarely) development of blood clots.</p><p>Not all of the symptoms described are necessarily related to unwanted overstimulation of the ovaries.</p><p>The risk of unwanted overstimulation can be minimised by careful monitoring of the follicle development during treatment. Contact your doctor immediately if you experience any abdominal complaints, even if they occur several days after the last injection was given.</p><p>&nbsp;</p><p>Rarely, blood clots may occur without unwanted overstimulation of the ovaries (see also section&nbsp;2: &lsquo;Warnings and precautions&rsquo;).</p><p>&nbsp;</p><p style="margin-left:0in"><strong>If you </strong><strong>are a man</strong></p><p>In men, fluid and salt may be retained in the tissues, marked usually by swelling of the ankles or feet and, in rare cases, enlargement of the breasts. This may be caused by increased androgen production due to treatment with hCG. If any of these symptoms appear, tell your doctor immediately.</p><p>&nbsp;</p><p>If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in">Keep out of the reach and sight of children.</p><p>Store at 2-15&deg;C, Store in the original package, in order to protect from light. Don&rsquo;t Freeze.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the package after &lsquo;EXP&rsquo;. There you will see a month and a year. The expiry date is the last date of that month.</p><p>&nbsp;</p><p>Do not use Pregnyl if you notice that the reconstituted solution contains particles or if the solution is not clear.</p><p>&nbsp;</p><p>Medicines should not be flushed down the drain or the toilet, and do not dispose of them with household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will ensure that they are disposed of responsibly and do not end up in the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in"><strong>What Pregnyl contains</strong></p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->The active ingredient is human chorionic gonadotropin (hCG), in doses of 1500&nbsp;IU or 5000&nbsp;IU per ampoule.</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->The other ingredients of this medicine are mannitol, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate anhydrous and sodium carboxymethylcellulose. The solvent contains sodium chloride (9&nbsp;mg) and water for injection (1.0&nbsp;ml).</p><p style="margin-left:14.2pt; margin-right:0in">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                One ampoule contains a white dry powder or cake, which is reconstituted with the solvent from the other ampoule. The solvent is a clear, colourless watery solution.

Pregnyl 1500
-	One pack contains 3, 6 or 10 ampoules of 2 ml with powder for injection, equivalent to 1500 IU hCG, and 3, 6 or 10 ampoules that each contain 1 ml of solvent.

Pregnyl 5000
-	One pack contains 1, 3 or 10 ampoules of 2 ml with powder for injection, equivalent to 5000 IU hCG, and 1, 3 or 10 ampoules that each contain 1 ml of solvent.

Not all pack sizes listed may be available on the market.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in"><strong>Marketing Authori</strong><strong>z</strong><strong>ation Holder and Manufacturer:</strong></p><p>N.V. Organon</p><p>Kloosterstraat 6</p><p>5349 AB Oss, The Netherlands</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
This leaflet was last approved in October 2012.
Version No. (02)

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">بريجنيل يحتوي على هرمون يعرف باسم موجهة الغدد التناسلية المشيمية البشرية (اتش سي جي)، الذي ينتمي إلى مجموعة من الأدوية تسمى الجونادوتروبين. وهي مهمة للخصوبة والتناسل.</p><p dir="RTL">يتم الحصول على بريجنيل من بول النساء الحوامل. (اتش سي جي) له نفس التأثير على الجسم حيث الهرمون اللوتيني (LH)، الذي يتم إنتاجه في الغدة النخامية من الرجال والنساء. الغدة النخامية هي المنتجة للهرمونات، غدة صغيرة تقع في قاعدة الدماغ. جنبًا إلى جنب مع هرمون الغدة النخامية ، الهرمون المنبه للجريب (FSH)، والهرمون اللوتيني (LH) يعملون على تنظيم وظيفة الجهاز التناسلي (المبايض في النساء والخصيتين عند الرجال). هذه الهرمونات هي ضرورية للنمو الطبيعي ونضج البويضات والحيوانات المنوية.</p><p dir="RTL"><strong>في</strong><strong> النساء</strong><br />&bull; في النساء، الهرمون المنبه للجريب (FSH) والهرمون اللوتيني (LH) هما المسؤولان عن النضج الشهري لبويضة في أحد المبيضين. وهناك حاجة أيضا للهرمون اللوتيني (LH ) للإباضة: انتاج البويضات. إذا كان الجسم لا ينتج ما يكفي من الهرمون المنبة للجريب (FSH)والهرمون اللوتيني (LH ) من تلقاء نفسه، &nbsp;يمكن أن يؤدي هذا إلى انخفاض الخصوبة. الحقن اليومي لهرمون المنبه للجريب (FSH) يساعد على نضج البويضة. بريجنيل يضمن أن التبويض يحدث بعد ذلك.<br />&bull; يمكن أيضا وصف بريجنيل مع تقنيات المساعدة على الإنجاب، قبل وبعد التبويض على حد سواء.</p><p dir="RTL"><strong>في</strong><strong> الرجال</strong><br />&bull; في الرجال، &nbsp;يمكن استخدام بريجنيل بمفرده أو مع دواء آخر يحتوي على الهرمون المنبه للجريب (FSH)، عندما يكون هناك ضعف في الغدد الجنسية أو عندما تكون هناك مشاكل مع تشكيل الحيوانات المنوية.</p><p dir="RTL"><strong>في الأولاد</strong><br />&bull; في الأولاد، &nbsp;يمكن استخدام بريجنيل &nbsp;عند تأخر سن البلوغ، بمفرده أو مع دواء اخر يحتوي على الهرمون المنبه للجريب (FSH).<br />&bull; في بعض الحالات يمكن أيضا إعطاء بريجنيل للأولاد الذين لم تنزل إحدى أو كلا الخصيتين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0in; margin-right:.25in" dir="RTL">لا تستخدم برجنيل<br />&bull; إذا كنت تعاني من حساسية (الحساسية المفرطة) تجاه أي من مكونات هذا الدواء (المدرجة في القسم6).<br />&bull; إذا كنت تعرف أو تشك أنه لديك ورم يرتبط بالهرمونات الجنسية في المبيض أو الثدي أو الرحم أو البروستاتا أو الخصيتين أو الدماغ (الغدة النخامية أو غدة تحت المهاد).<br />&bull; إذا كانت الغدد التناسلية لديك (المبيضين أو الخصيتين) لا تعمل، ويرجع ذلك إلى ما يسمى ب &quot;فشل الغدد التناسلية&quot;.<br />&bull; إذا كنتِ امرأة وكنت تعانين من تشوهات في الأعضاء التناسلية التي تجعل الحمل مستحيلًا.<br />&bull; إذا كنتِ امرأة وكنت تعانين من الأورام الليفية الرحمية (myomas)، والتي تجعل الحمل مستحيلًا.<br />&bull; إذا كنتِ امرأة وكنتِ تعانين من نزيف مهبلي شديد وغير مبرر أو غير منتظم.<br />&bull; إذا كنتِ امرأة وكنتِ تعانين من تكيسات المبايض أو تضخم المبيضين، لا علاقة لمتلازمة تكيس المبايض (PCOS)، وهي الحالة التي تجعل البويضات لاتنضج ولا يحدث تبويض).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات و</strong><strong>الاحتياطات</strong><br />تحدث إلى طبيبك أو الصيدلي قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للرجال والنساء</strong><br />- يجب إستثناء وجود غدد لم تخضع للعلاج غير الغدد التناسلية (غير مرتبطة بالغدد التناسلية) أو الغدد الصماء (الهرمونات) غير طبيعية (مثل أمراض الغدة الدرقية، الغدة الكظرية أو الغدة النخامية).<br />- يجب ألّا يستخدم بريجنيل لإنقاص الوزن. (اتش سي جي) ليس له تأثير على التمثيل الغذائي للدهون (حرق الدهون)، وتوزيع الدهون أو الشهية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للنساء</strong><br />مهم جدًا وجود إشراف دقيق من قبل الطبيب.</p><p style="text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان العلاج مع نتائج الجونادوتروبين في الحمل، هناك خطر متزايد من وجود التوائم أو الولادات المتعددة.</p><p style="text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->خطر الحمل خارج الرحم هو أعلى قليلًا في النساء اللواتي يعانين من قناة فالوب المتضررة.</p><p style="text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;قد يكون هناك خطر أعلى قليلًا من الاجهاض في النساء اللواتي يخضعن لعلاج للخصوبة.</p><p style="text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تعدد الحمل وخصائص المرضى الذين يخضعون لعلاج الخصوبة (مثل سن المرأة، وخصائص الحيوانات المنوية) قد تحمل خطرًا متزايدًا من التشوهات الخلقية. لا يوجد أيّ دليل على أن استخدام الجونادوتروبين نفسه يزيد من خطر التشوهات الخلقية.</p><p style="text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يتم إجراء التصوير بالموجات فوق الصوتية عادة للمبيضين بشكل منتظم ويتم أخذ عينات الدم بانتظام . نتائج هذه الاختبارات تسمح للطبيب بإختيار الجرعة اليومية المناسبة من الهرمون المنبه للجريب (FSH). وهذا أمر مهم جدًا، لأن الجرعات العالية جدا من الجونادوتروبين قد تؤدي إلى مضاعفات نادرة هي التحفيز الشديد للمبايض. قد تلاحظين ألم في البطن،غثيان أو إسهال، آلام في الثدي، قراءات غير طبيعية مؤقتًا في اختبارات وظائف الكبد. في حالات نادرة، عندما يتطور شكل حادّ من متلازمة التحفيز الشديد للمبايض، والتي يمكن أن تكون مهددة للحياة. هذا التحذير مهم بشكل خاص للمرضى الذين يعانون من متلازمة تكيس المبايض (PCOS). المراقبة المنتظمة لاستجابة العلاج بواسطة جونادوتروبين يساعد طبيبك على تجنب التحفيز الشديد للمبايض.<br />يجب إبلاغ الطبيب فورًا إذا كان لديك ألم في البطن.</p><p style="text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->العلاج بواسطة بريجنيل (مثل الحمل) قد يؤدي إلى خطر أعلى قليلًا بالاصابة بجلطة (تشكيل لتجلط الدم في الأوعية الدموية، في معظم الأحيان في أوردة الساقين أو الرئتين). ناقشي هذا الأمر مع طبيبك قبل البدء في العلاج، خاصة إذا:</p><p style="margin-left:0in; margin-right:1.5in; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->كنتِ تعرفين أن لديك زيادة خطر بالإصابة بتجلط</p><p style="margin-left:0in; margin-right:1.5in; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->أنتِ أو أيّ شخص في عائلتك، أُصيب (أو أُصيب في الماضي) بتجلط الدم</p><p style="margin-left:0in; margin-right:1.5in; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;كنتِ تعانين من السمنة المفرطة.</p><p style="margin-left:0in; margin-right:39.15pt; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->اختبار الحمل قد يعطي نتيجة إيجابية كاذبة بعد تناول برجنيل لمدة تصل إلى 10ايام.</p><p style="margin-left:0in; margin-right:39.15pt" dir="RTL">&nbsp;</p><p dir="RTL"><strong>للرجال</strong></p><p style="margin-left:0in; margin-right:39.15pt; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->العلاج بواسطة (اتش سي جي) يمكن أن يؤدي إلى إنتاج أجسام مضادة لها (البروتينات المضادة لتأثير اتش سي جي). في حالات نادرة هذا يمكن أن يؤدي الى عدم فعالية العلاج.</p><p style="margin-left:0in; margin-right:39.15pt; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->العلاج بواسطة (اتش سي جي) يؤدي إلى زيادة إنتاج الاندروجين (هرمون الذكورة). لذلك، إشراف دقيق من قبل الطبيب مهم جدًا إذا كنتَ تعاني (أو عانيت سابقًا) من:<br />&bull; أمراض القلب والشرايين<br />&bull; أمراض الكلى<br />&bull; ضغط دم مرتفع<br />&bull; الصرع<br />&bull; الصداع النصفي<br />لأن زيادة إنتاج الاندروجين قد تكون في بعض الحالات تؤدي إلى تفاقم أو تكرار هذه الأعراض.</p><p dir="RTL"><strong>الأطفال</strong><strong> والمراهقين حتى سن 18 عاما</strong></p><p dir="RTL">الإشراف الإضافي من قبل الطبيب ضروري عند معالجة الأولاد الذين لم يبلغوا بعد سن البلوغ. وذلك لأن بريجنيل يمكن أن يحفز النمو الجنسي المبكر وقد يؤدي إلى إبطاء النمو.</p><p dir="RTL"><strong>الأدوية الأخرى وبرجنيل</strong></p><p dir="RTL">لم تُدرس آثار بريجنيل على الأدوية الأخرى. بالتالي، لا يمكن استبعاد التفاعلات مع الأدوية التي تستخدم عادة.</p><p dir="RTL">اخبر طبيبك أو الصيدلي إذا كنت تأخذ، تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL"><strong>الحمل و</strong><strong>الرضاعة الطبيعية</strong><br />يجب عدم استخدام بريجنيل خلال فترة الحمل. بريجنيل يمكن استخدامه لدعم الحمل خلال فترة بعد التبويض (مرحلة الجسم الأصفر).<br />إذا كنتِ إمرأة، اسألي طبيبكِ للحصول على المشورة قبل تناول هذا الدواء. يمكن استخدام بريجنيل خلال فترة الرضاعة الطبيعية للطفل.</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong><br />بقدر ما هو معروف، ليس له أي تأثير على القدرة على القيادة أو تشغيل الآلات.<br /><strong>بريجنيل يحتوي على</strong><strong> الصوديوم</strong><br />هذا الدواء يحتوي على أقل من 1 مليمول من الصوديوم (23 ملغ) في الحقنة، أي خالي من الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0in; margin-right:.25in; text-indent:-.25in" dir="RTL"><!--[if !supportLists]--><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>كيفية استخدام</strong><strong> برجنيل</strong><br /><strong>الجرعة</strong><br />دائمًا استخدم هذا الدواء كما وصفه الطبيب لك &nbsp;تمامًا. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا. طبيبك سوف يقرر مقدار الجرعة من بريجنيل وسيشرف على حقنتك الأولى.<br />في المرضى من النساء، عادة ما تعطى حقنة واحدة لتنشيط الإباضة وتصل إلى 3 حقن لدعم مرحلة الجسم الأصفر التي تليها.<br />في المرضى الذكور (الرجال والفتيان) تعطى الحقن مرتين أو 3 مرات في الأسبوع. إن العلاج يستمر من بضعة أسابيع إلى 3 أشهر على الأقل، اعتمادًا على المشكلة التي يتم علاجها. طول فترة العلاج تعتمد على الوقت اللازم لتطوير الحيوانات المنوية والفترة التي يمكن الشعور فيها بتحسن.</p><p style="margin-left:0in; margin-right:.25in" dir="RTL"><strong>كيف</strong><strong> يتم إعطاء الحقن</strong><br />يجب حل مسحوق للحقن مع السائل من أمبولة آخرى (المذيب). يجب استخدام هذا المحلول على الفور بعد ذلك. يمكن حقن محلول بريجنيل ببطء في العضلات (على سبيل المثال، في الأرداف أو الفخذ أو الذراع) أو تحت الجلد مباشرة (على سبيل المثال، في أسفل البطن). عند الحقن في العضل، يجب أن تعطى الحقنة من قِبل الطبيب أو الممرضة. عندما تعطى تحت الجلد، في بعض الحالات، تعطى الحقن من قبل نفسك أو شريكك. طبيبك سوف يصف لك متى وكيفية القيام بذلك. إذا كنت ترغب فى حقن نفسك، اتبع الإرشادات الموجودة في الجزء التالي، بحيث يمكنك أخذ بريجنيل بشكل صحيح ومع الحد الأدنى من عدم الراحة من الحقن.</p><p style="margin-left:0in; margin-right:.25in" dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Illu" style='width:83pt;height:115.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title="Illu"/>
</v:shape><![endif]--><!--[if !vml]--><img width="111" height="154" alt="Illu" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /><!--[endif]--></p><p style="margin-left:0in; margin-right:.25in" dir="RTL"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:.25in" dir="RTL"><strong>تعليمات الاستخدام</strong><br /><em>الخطوة 1 - إعداد حقن حقنة</em><br />يجب حل المواد الجافة في الأمبولة الزجاجيّة في المذيب من الأمبولة الزجاجيّة الأخرى. للقيام بذلك، أولًا اكسر أعلى أمبولة المذيب (الشكل أ)، مع الحفاظ على البقعة السوداء في المكان كما هو مبين في الشكلين (أ) و(ج). امسك بقطعة من الشاش بين الأمبولة وأصابعك لتجنب جرح نفسك من حافة الزجاج المكسور. اسحب المذيب من خلال الإبرة إلى الحقنة (الشكل ب). ثم اكسر أعلى أمبولة المواد الجافة (الشكل ج). احقن المذيب في أمبولة المواد الجافة (الشكل د). لا ترجه، ولكن حركة بلطف حتى يصبح المحلول صافي. عادة يذوب بريجنيل فورًا.يجب إلّا تسخدم المحلول إذا كان يحتوي على جزيئات أو اذا كان مضببًا. تأكد من حقن كامل المذيب والمحافظة على ظروف معقمة (على سبيل المثال، لا تضع الحقنة إلى أسفل دون وضع الغطاء الواقي على الإبرة). اسحب محلول بريجنيل ليصل إلى الحقنة الفارغة (الشكل هـ)، استبدل الإبرة المستخدمة لوضع المحلول بإبرة معقمة (الشكل و). ادخل الإبرة الجديدة بالحقنة وامسك بالحقنة بإتجاه الأعلى، اضغط على الجانب بلطف للسماح لفقاعات الهواء بأن ترتفع إلى الأعلى. ثم، ادفع المكبس حتى يخرج كل الهواء من الحقنة ويبقى محلول بريجنيل وحدة موجود في حقنة (الشكل ز).</p><p style="margin-left:0in; margin-right:.25in" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:.25in" dir="RTL"><em>الخطوة 2</em><em> - موقع الحقن</em><br />أفضل موقع للحقن تحت الجلد في البطن حول السرة (الشكل ح)، حيث هناك الكثير من الجلد المترهل وطبقات من الأنسجة الدهنية. مواقع الحقن الأخرى ممكنة أيضًا. اختر مكانًا مختلفًا بعض الشيء عند كل حقنة. سينصحك الطبيب أو الممرضة عن أماكن الحقن.</p><p style="margin-left:0in; margin-right:.25in" dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:38.65pt;margin-top:11.95pt;width:29.9pt;height:18.4pt;z-index:251654144;
 visibility:visible;mso-width-relative:margin;mso-height-relative:margin'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#Text_x0020_Box_x0020_2'/>
</v:shape><v:shape id="_x0000_s1029" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:213.1pt;margin-top:11.95pt;width:29.9pt;
 height:18.4pt;z-index:251656192;visibility:visible;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1029'/>
</v:shape><v:shape id="_x0000_s1030" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:298.35pt;margin-top:11.95pt;width:29.9pt;
 height:18.4pt;z-index:251657216;visibility:visible;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1030'/>
</v:shape><v:shape id="_x0000_s1028" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:124.5pt;margin-top:11.95pt;width:29.9pt;
 height:18.4pt;z-index:251655168;visibility:visible;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1028'/>
</v:shape><![endif]--><!--[if !vml]--></p><table align="left" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="background-color:white; border-color:black; vertical-align:top"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p style="text-align:center" dir="RTL"><strong>أ</strong></p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td><td>&nbsp;</td><td style="background-color:white; border-color:black; vertical-align:top"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p style="text-align:center" dir="RTL"><strong>ب</strong></p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td><td>&nbsp;</td><td style="background-color:white; border-color:black; vertical-align:top"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p style="text-align:center" dir="RTL"><strong>ج</strong></p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td><td>&nbsp;</td><td style="background-color:white; border-color:black; vertical-align:top"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p style="text-align:center" dir="RTL"><strong>د</strong></p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]-->&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="Picture_x0020_10" o:spid="_x0000_i1026"
 type="#_x0000_t75" alt="Illu" style='width:83pt;height:123pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
  o:title="Illu"/>
</v:shape><![endif]--><!--[if !vml]--><img width="111" height="164" alt="Illu" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /><!--[endif]-->&nbsp;<!--[if gte vml 1]><v:shape id="Picture_x0020_9" o:spid="_x0000_i1028"
 type="#_x0000_t75" alt="Illu" style='width:83pt;height:125pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
  o:title="Illu"/>
</v:shape><![endif]--><!--[if !vml]--><img width="111" height="167" alt="Illu" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /><!--[endif]-->&nbsp;<!--[if gte vml 1]><v:shape id="Picture_x0020_8" o:spid="_x0000_i1029"
 type="#_x0000_t75" alt="Illu" style='width:83pt;height:123pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image007.jpg"
  o:title="Illu"/>
</v:shape><![endif]--><!--[if !vml]--><img width="111" height="164" alt="Illu" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image008.jpg" /><!--[endif]-->&nbsp;<!--[if gte vml 1]><v:shape id="Picture_x0020_7" o:spid="_x0000_i1030"
 type="#_x0000_t75" alt="Illu" style='width:83pt;height:125pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image009.jpg"
  o:title="Illu"/>
</v:shape><![endif]--><!--[if !vml]--><img width="111" height="167" alt="Illu" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image010.jpg" /><!--[endif]-->&nbsp;<!--[if gte vml 1]><v:shape id="Picture_x0020_6" o:spid="_x0000_i1031"
 type="#_x0000_t75" alt="Illu" style='width:83pt;height:123pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image011.jpg"
  o:title="Illu"/>
</v:shape><![endif]--><!--[if !vml]--><img width="111" height="164" alt="Illu" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image012.jpg" /><!--[endif]--></p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="_x0000_s1035" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:389.6pt;margin-top:33.7pt;width:29.9pt;height:18.4pt;
 z-index:251662336;visibility:visible;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1035'/>
</v:shape><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td style="background-color:white; border-color:black; vertical-align:top"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p style="text-align:center" dir="RTL"><strong>ط</strong></p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1034" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:298.35pt;
 margin-top:-.25pt;width:29.9pt;height:18.4pt;z-index:251661312;visibility:visible;
 mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1034'/>
</v:shape><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td style="background-color:white; border-color:black; vertical-align:top"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p style="text-align:center" dir="RTL"><strong>ح</strong></p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1032" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:213.1pt;
 margin-top:-.25pt;width:29.9pt;height:18.4pt;z-index:251659264;visibility:visible;
 mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1032'/>
</v:shape><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td style="background-color:white; border-color:black; vertical-align:top"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p style="text-align:center" dir="RTL"><strong>ز</strong></p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1033" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:385.25pt;
 margin-top:-133.9pt;width:29.9pt;height:18.4pt;z-index:251660288;visibility:visible;
 mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1033'/>
</v:shape><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td style="background-color:white; border-color:black; vertical-align:top"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p style="text-align:center" dir="RTL"><strong>ه</strong></p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1031" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:124.5pt;
 margin-top:-.25pt;width:29.9pt;height:18.4pt;z-index:251658240;visibility:visible;
 mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1031'/>
</v:shape><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td style="background-color:white; border-color:black; vertical-align:top"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p style="text-align:center" dir="RTL"><strong>و</strong></p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]--><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_11"
 o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:389.6pt;margin-top:12.45pt;width:71.8pt;height:13.5pt;
 z-index:251653120;visibility:visible;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" o:allowincell="f" stroked="f">
 <v:textbox style='mso-next-textbox:#Text_x0020_Box_x0020_11' inset="0,0,0,0"/>
</v:shape><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td style="background-color:white; vertical-align:top"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p style="text-align:center" dir="RTL"><strong>تحت الجلد</strong></p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]--><em><!--[if gte vml 1]><v:shape id="Picture_x0020_5" o:spid="_x0000_i1027"
 type="#_x0000_t75" alt="Illu" style='width:83pt;height:125pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image013.jpg"
  o:title="Illu"/>
</v:shape><![endif]--><!--[if !vml]--><img width="111" height="167" alt="Illu" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image014.jpg" /><!--[endif]--></em><em>&nbsp;</em><em><!--[if gte vml 1]><v:shape id="Picture_x0020_4" o:spid="_x0000_i1032"
 type="#_x0000_t75" alt="Illu" style='width:83pt;height:123pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image015.jpg"
  o:title="Illu"/>
</v:shape><![endif]--><!--[if !vml]--><img width="111" height="164" alt="Illu" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image016.jpg" /><!--[endif]--></em><em>&nbsp;</em><em><!--[if gte vml 1]><v:shape id="Picture_x0020_3" o:spid="_x0000_i1033"
 type="#_x0000_t75" alt="Illu" style='width:83pt;height:125pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image017.jpg"
  o:title="Illu"/>
</v:shape><![endif]--><!--[if !vml]--><img width="111" height="167" alt="Illu" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image018.jpg" /><!--[endif]--></em><em>&nbsp;</em><!--[if gte vml 1]><v:shape id="Picture_x0020_2" o:spid="_x0000_i1034"
 type="#_x0000_t75" alt="Illu  Puregon i-nieuw (2)" style='width:84pt;height:126pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image019.jpg"
  o:title="Illu  Puregon i-nieuw (2)"/>
</v:shape><![endif]--><!--[if !vml]--><img width="112" height="168" alt="Illu  Puregon i-nieuw (2)" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image020.jpg" /><!--[endif]--></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:.25in" dir="RTL">&nbsp;</p><p dir="RTL"><em>الخطوة 3</em><em> - إعداد موقع الحقن</em><br />اضغط عدة مرات على موقع الحقن لتحفيز النهايات العصبية الصغيرة. هذا يقلل من الألم عند دخول الإبرة تحت الجلد. غسّل اليدين وتنظيف موقع الحقن بمسحة تحتوي على مطهر (على سبيل المثال الكلورهيكسيدين 0.5٪) لإزالة أي بكتيريا على السطح. نظّف مساحة حوالي خمسة سنتيمترات (بوصتين) حول موقع الحقن، انتظر حتى يجف المطهر لمدة دقيقة واحدة على الأقل قبل أن تذهب إلى الخطوة التالية.</p><p dir="RTL"><em>الخطوة 4</em><em> - إدخال الإبرة</em><br />اضغط على سطح الجلد بين الإبهام والسبابة. باليد الأخرى، ادخل الإبرة إلى الجلد المثني بزاوية 45 درجة، كما هو مبين في الشكل ط.</p><p dir="RTL"><em>الخطوة 5</em><em> - التحقق من موضع &nbsp;الإبرة الصحيح</em><br />اسحب المكبس من الحقنة بلطف، للتأكد من أن الإبرة في الموضع الصحيح. إذا تم سحب الدم إلى الحقنة، فإنه يعني تم ثقب الوريد. إذا حدث هذا، إزالة الإبرة من الجلد والضغط على موقع الحقن مع مسحة يحتوي على مطهر؛ يجب أن يتوقف النزيف بعد حوالي دقيقتين. لا تستخدم المحلول الملوث بالدم. ابدأ من جديد من الخطوة 1 باستخدام حقنة جديدة، وإبرة جديدة، وأمبولة جديدة من بريجنيل والمذيب.</p><p dir="RTL"><em>خطوة</em><em> 6 - حقن ال</em><em>م</em><em>حلول</em><br />اضغط المكبس ببطء ولكن بثبات. بهذه الطريقة سوف يتم حقن المحلول بشكل صحيح دون إصابة العضلات أو الأنسجة تحت الجلد.</p><p dir="RTL"><em>خطوة</em><em> 7 - إخراج الحقنة</em><br />بحركة سريعة، اسحب الإبرة من الجلد واضغط على موقع الحقن بمسحة تحتوي على مطهر. دلّك البشرة بلطف - من خلال عمل الضغط - يساعد ذلك على تفريق محلول بريجنيل بسهولة أكثر ويقلل من الألم. يجب التخلص من أي محلول متبقي. لا تخلط بريجنيل مع أي أدوية أخرى.</p><p dir="RTL"><em>الخطوة 8</em><em> - التخلص من الإبر</em><br />ضع الحقنة مرة أخرى في الغلاف الوقائي لمنع الإصابة.<br />تصرف بعناية مع جميع الإبر التي استخدمتها. يمكنك إما أن تتخلص من الإبر في حاوية الأدوات الحادة أو نقلها الى الصيدلية ليتم اتلافها. لا تبادل الإبر أو الحقن مع الآخرين.</p><p dir="RTL"><strong>إذا استخدمت بريجنيل أكثر مما يجب</strong><br />إذا استخدمت جرعة زائدة من برجنيل، اتصل بطبيبك أو الصيدلي فورًا.<br />سُمّيّة بريجنيل منخفضة جدًا، ولكن الجرعة &nbsp;الزائدة جدًا من يمكن أن تسبب متلازمة التحفيز الشديد للمبايض (انظر أيضًا البند 2، &quot;التحذيرات والاحتياطات&quot; و البند 4 &quot;الآثار الجانبية المحتملة &quot;).</p><p dir="RTL"><strong>إذا</strong><strong> نسيت استخدام برجنيل</strong><br />لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.<br />اخبر طبيبك عن الجرعة الفائتة.</p><p dir="RTL">إذا كان لديك أيّ أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثارًا آجانبية، وإن كانت لاتصيب الجميع. معظم هذه التفاعلات هي ذات طبيعة معتدلة وتزول من تلقاء نفسها.<br />تحدث الآثار الجانبية الشائعة لأقل من شخص واحد لكل 10 مرضى.<br />تحدث الآثار الجانبية غير الشائعة لأقل من شخص واحد لكل 100 مريض.<br />تحدث الآثار الجانبية النادرة لأقل من شخص واحد لكل 1000 مريض.<br /><br />بريجنيل يمكن أن يسبب كدمات، ألم، احمرار وتورم وحكة في موقع الحقن. الحساسية نادرة، وتنطوي في الغالب على الألم أو الطفح في موقع الحقن.<br />في حالات نادرة يمكن أن يحدث فرط الحساسية العامة، مثل الطفح الجلدي في عدة مناطق من الجسم أو الحمى.</p><p dir="RTL"><strong>للنساء</strong><br />إذا تم تحفيز المبايض عن طريق اعطاء الهرمون المحفز للحويصلة &nbsp;(FSH ) وتم إعطاء برجنيل، فإنه قد يؤدي إلى التحفيز الشديد للمبايض غير المرغوب فيه . فرط التحفيز المعتدل هو شائع، ويمكن أن يرى على النحو التالي:<br />- ألم في البطن أو المعدة، والغثيان، والإسهال أو الإحساس بالانتفاخ.<br />- ألم في الثدي<br />- تضخم المبايض من خفيفة إلى متوسطة<br />- تكيسات المبايض.</p><p dir="RTL">التحفيز الشديد للمبايض أمر نادر الحدوث. قد يكون مصحوبًا بِـ :<br />- تكيس مبيض كبير<br />- ألم مفاجئ في البطن<br />- احتباس السوائل في تجاويف الصدر والبطن (استسقاء)<br />- زيادة الوزن<br />- (نادرًا) تكون جلطات الدم.<br />ليست كل الأعراض المذكورة هي بالضرورة ذات صلة بالتحفيز الشديد للمبايض.<br />يمكن التقليل من خطر التحفيز الشديد للمبايض من خلال المراقبة الجيدة لتطور الحويصلة خلال العلاج. اتصل بطبيبك على الفور إذا شعرت بأي مضاعفات في البطن، حتى لوحدثت بعد عدة أيام من آخر حقن.<br />نادرًا، قد تحدث جلطات الدم دون حدوث تحفيز شديد للمبايض (انظر أيضا البند 2: التحذيرات والاحتياطات).</p><p dir="RTL"><strong>للرجال</strong><br />في الرجال، السوائل والملح يمكن الاحتفاظ بها في الأنسجة، وتتميز عادة عن طريق تورم الكاحلين والقدمين وفي حالات نادرة تضخم الثديين. قد يكون سبب ذلك زيادة إنتاج الاندروجين بسبب العالج بواسطة ( اتش سي جي). إذا ظهرت اي من هذه الاعراض، اخبر طبيبك فورًا.<br /><br />إذا كانت أي من الآثار الجانبية خطيرة، أو إذا لاحظت أي آثار جانبية غير تلك المذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال.<br />يُحفظ في درجة حرارة من ٢ إلى ١٥&nbsp; درجة مئوية،&nbsp; يُحفظ في العبوة الأصلية لحمايته من الضوء . لا يُجمد.<br />&nbsp;</p><p dir="RTL"><br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الوارد على العبوة بعد &quot;EXP&quot;. تاريخ انتهاء الصلاحية هو آخر يوم من ذلك الشهر.<br />لا تستخدم بريجنيل إذا لاحظت أن المحلول يحتوي على جزيئات أو إذا كان هذا المحلول غير صافٍ.<br />لا تتخلّص من الأدوية في المراحيض أو في نظام الصرف الصحي المنزلي. اسأل الصيدلي عن كيفيّة التخلّص من الأدوية التي لم تعُد تستعملها. فيتمّ التخلّص منها بطريقة مسؤولة ولا ينتهي بها الأمر إلى تلويث البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">على ماذا يحتوي بريجنيل<br />- المادة الفعالة موجهة الغدد التناسلية المشيمية البشرية (اتش سي جي)، في جرعات من 1500 وحدة دولية أو 5000 وحدة دولية في أمبولة.<br />- المكونات الأخرى من هذا الدواء هي مانيتول، ثنائي الصوديوم فوسفات الهيدروجين لامائي، والصوديوم ثنائي الهيدروجين فوسفات لامائي، &nbsp;وكربوكسي ميثيل سلولوز الصوديوم. يحتوي على مذيب كلوريد الصوديوم (9 ملغ) والماء للحقن (1 مل).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحتوي على أمبولة واحدة تحتوي على مسحوق جاف أبيض ، و الذي يتم إذابته مع المذيب من الأمبولة الأخرى. المذيب هو محلول مائي عديم اللون وصافٍ.<br /><u>بريجنيل 1500</u><br />- عبوة واحدة تحتوي على أمبولة واحدة أو 3 أو 10 أمبولات من 2 مل من مسحوق للحقن، أي ما يعادل 1500 وحدة دولية من (اتش سي جي)، و 3 أو 6 أو 10 أمبولات تحتوي على 1 مل من المذيب.<br /><u>بريجنيل 5000</u><br />- عبوة واحدة تحتوي على أمبولة واحدة أو 3 أو 10 أمبولات من 2 مل من مسحوق للحقن، أي ما يعادل 5000 وحدة دولية من (اتش سي جي)، و عبوة واحدة أو 3 أو 10 أمبولات تحتوي على 1 مل من المذيب.<br /><br />قد لايتم تسويق جميع الاحجام.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة المالكة لحقوق التسويق و الشركة الصانعة:</p><p dir="RTL">إن في أورجانون</p><p dir="RTL">كلوستيرسترات 6،</p><p dir="RTL">5349 أيه بي أوس،</p><p dir="RTL">هولندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمّت آخر مراجعة لهذه النشرة بتاريخ اكتوبر 2012
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pregnyl 1500 I.U., powder and solvent for solution for injection
Pregnyl 5000 I.U., powder and solvent for solution for injection


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pregnyl consists of a freeze-dried powder for injection and a solvent for reconstitution. The active ingredient [human chorionic gonadotropin (hCG)], which is obtained from the urine of pregnant women, has luteinizing hormone (LH) activity.
An ampoule contains 1500 or 5000 I.U. hCG.
Excipient with known effect: sodium. This medicinal product contains less than 1 mmol sodium (23 mg) per daily dose, i.e. essentially “sodium-free”.
For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection (powder and solvent for injection). The powder is a white, dry powder or cake. The solvent is a clear and colourless, aqueous solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>Therapeutic indications</strong></p><p>&nbsp;</p><p style="text-align:left; text-indent:28.35pt"><em>In the female:</em></p><p style="margin-left:49.65pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Ovulation induction in subfertility due to anovulation or impaired follicle-ripening.</p><p style="margin-left:49.65pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Preparation of follicles for puncture in controlled ovarian hyperstimulation programs (for medically assisted reproductive techniques).</p><p style="margin-left:49.65pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Luteal phase support in women undergoing controlled ovarian hyperstimulation (in medically assisted reproductive programs) using GnRH analogs or after ovulation induction in cases of infertility due to anovulation in the absence of endogenous estrogenous activity (WHO group I).</p><p style="text-align:left; text-indent:21.3pt">&nbsp;</p><p style="text-align:left; text-indent:28.35pt">In the male:</p><p style="margin-left:28.35pt; text-align:left; text-indent:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Hypogonadotropic hypogonadism.</p><p style="margin-left:28.35pt; text-align:left; text-indent:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Subfertility associated with idiopathic impaired spermatogenesis.</p><p style="text-align:left; text-indent:21.3pt">&nbsp;</p><p style="text-indent:28.35pt"><em>Male pediatric patients:</em></p><p style="margin-left:0in; text-align:left; text-indent:28.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Delayed puberty associated with insufficient gonadotropic pituitary function.</p><p style="margin-left:0in; text-align:left; text-indent:28.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Cryptorchidism, not due to anatomical obstruction.</p><p style="text-align:left">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>Posology&nbsp;and&nbsp;method&nbsp;of&nbsp;administration</strong></p><p style="margin-left:28.35pt; margin-right:0in">Treatment with Pregnyl should be initiated under the supervision of a physician experienced in the treatment of fertility problems.</p><p style="margin-left:28.35pt; margin-right:0in">The first injection of Pregnyl should be performed under direct medical supervision.</p><p style="text-align:left; text-indent:28.35pt">Dosage&nbsp;in&nbsp;the&nbsp;female:</p><p style="margin-left:49.65pt; margin-right:-.05pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Ovulation induction associated with subfertility due to impaired follicle ripening or&nbsp; anovulation:</u><br />Usually one injection of 5000-10,000 I.U. following treatment with an FSH or hMG preparation.</p><p style="margin-left:49.65pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Preparation of follicles for puncture in controlled ovarian hyperstimulation programs:</u></p><p style="margin-left:49.6pt; text-align:left">Usually one injection of 5000 or 10,000 I.U. following treatment with a FSH- or hMG- preparation.</p><p style="margin-left:49.65pt; margin-right:-.05pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Luteal phase support, as part of controlled ovarian hyperstimulation programs:</u><br />Two to three repeat injections of 1000 to 3000 I.U. each may be given within nine days following ovulation or embryo transfer (for example on day 3, 6 and 9 after ovulation induction).</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left">Dosage&nbsp;in&nbsp;the&nbsp;male:</p><p style="margin-left:28.35pt; text-align:left">The dosages given below are indicative and have to be adjusted individually, guided by the clinical response.</p><p>&nbsp;</p><p style="margin-left:49.6pt; text-align:left; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Hypogonadotropic hypogonadism and idiopathic impaired spermatogenesis:</u><br />1000-2000 I.U., two to three times per week. If the main complaint is subfertility associated with impaired spermatogenesis, Pregnyl may be given two to three times a week with a follitropin (FSH)- containing preparation. This treatment should be continued for at least three months before any improvement in spermatogenesis can be expected. During this treatment testosterone replacement therapy should be suspended. Once achieved, the improvement can sometimes be maintained by hCG alone.</p><p style="margin-left:49.6pt; text-align:left">&nbsp;</p><p style="margin-left:49.65pt; margin-right:-.05pt; text-align:left; text-indent:-21.3pt"><em>Dosage&nbsp;in&nbsp;male pediatric patients:</em></p><p style="margin-left:49.6pt; text-align:left; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Delayed puberty associated with insufficient gonadotropin pituitary function:</u><br />1500 I.U. two to three times a week for at least six months.</p><p style="margin-left:49.6pt; text-align:left; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Cryptorchidism, not due to an anatomical obstruction:</u><br />- under 2 years of age: 250 I.U. twice weekly for six weeks (see section 6.6 Pediatric dilution for instructions on how to prepare 250 I.U. from Pregnyl 1500&nbsp;I.U.);<br />- under 6 years of age: 500-1000 I.U. twice weekly for six weeks (see section 6.6 Pediatric dilution for instructions on how to prepare 500 I.U. from Pregnyl 1500&nbsp;I.U.);<br />- over 6 years of age: 1500 I.U. twice weekly for six weeks.<br />If necessary, this treatment can be repeated.</p><p style="margin-left:0in; margin-right:-.05pt; text-align:left">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in">Method of administration</p><p style="margin-left:28.35pt; margin-right:0in">Pregnyl should be reconstituted with the solvent included. The reconstituted solution should be administered immediately. It should be checked visually whether all freeze-dried material has dissolved completely. The reconstituted solution should not be used if it contains particles or is not clear.</p><p style="margin-left:28.35pt; margin-right:0in">To prevent painful injections and minimise leakage from the injection site, the Pregnyl solution should be slowly administered intramuscularly or subcutaneously. Any unused solution should be discarded.</p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">Subcutaneous injection of Pregnyl may be carried out by patient or partner, provided that proper instructions are given by the physician. Self-administration of Pregnyl should only be performed by patients who are well-motivated, adequately trained and with access to expert advice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Contraindications
For males and females:
•	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Known or suspected tumors of the ovary, breast, uterus, testis, prostate, pituitary gland or hypothalamus.
•	Primary gonadal failure.

Additionally for females:
•	Malformations of the genital organ that contraindicate pregnancy.
•	Fibroid tumours in the uterus that contraindicate pregnancy.
•	Unexplained vaginal bleeding.
•	Ovarian cysts or enlarged ovaries, not related to PCOS. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>Special&nbsp;warnings&nbsp;and&nbsp;precautions&nbsp;for&nbsp;use</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left; text-indent:28.35pt">For males and females:</p><p style="margin-left:42.55pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;&nbsp;The presence of uncontrolled non-gonadal endocrinopathies (e.g. thyroid, adrenal or pituitary disorders) should be excluded.</p><p style="margin-left:42.55pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;&nbsp;The active ingredient of this preparation is extracted from human urine. Therefore, the risk of a transmission of a pathogen (known or unknown) cannot be excluded. No cases of viral contamination associated with administration of gonadotropin extracted from human urine have been reported.</p><p style="margin-left:42.55pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;&nbsp;Patients on a controlled sodium diet: This medicinal product contains less than 1&nbsp;mmol sodium (23 mg) per daily dose, i.e. essentially &ldquo;sodium-free&rdquo;.</p><p style="margin-left:42.55pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;&nbsp;Pregnyl should not be used for body weight reduction. HCG has no effect on fat metabolism, fat distribution or appetite.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left; text-indent:28.35pt">Additionally for females:</p><p style="margin-left:49.65pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->In pregnancies occurring after induction of ovulation with gonadotropic preparations, there is an increased risk of a multiple birth.</p><p style="margin-left:49.65pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Since infertile women undergoing Assisted Reproduction Techniques (ART), and particularly IVF, often have tubal abnormalities, the incidence of ectopic pregnancies might be increased. Early ultrasound confirmation that a pregnancy is intrauterine is therefore important.</p><p style="margin-left:49.65pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Rates of pregnancy loss in women undergoing ART &nbsp;as well as in anovulatory patients are higher than in the normal population.</p><p style="margin-left:49.65pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The incidence of congenital malformations after ART as well as in anovulatory patients may be slightly higher than after spontaneous conceptions. This is thought to be due to differences in parental characteristics (e.g., maternal age, sperm characteristics) and a higher chance of multiple gestations. There are no signs that the use of gonadotropins in ART is associated with an increased risk of congenital defects.</p><p style="margin-left:49.65pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Unwanted&nbsp;ovarian hyperstimulation</u><br />In patients treated for subfertility due to anovulation or impaired follicular ripening, prior administration of an FSH-preparation may lead to unwanted ovarian hyperstimulation. Therefore, ultrasonic assessment of follicular development and determinations of estradiol levels should be performed prior to FSH-treatment and at regular intervals during FSH-treatment. Apart from the possible development of a high number of follicles at the same time, estradiol levels may rise very rapidly, e.g. more than a daily doubling for two or three consecutive days, which can result in extremely high values. The diagnosis of ovarian hyperstimulation may be confirmed by ultrasound examination. If this unwanted ovarian hyperstimulation occurs (i.e. not as part of a treatment preparing for IVF/ET, GIFT or ICSI), the administration of the FSH-containing preparation should be discontinued immediately. In that case pregnancy should be avoided and Pregnyl must not be given, because the administration of an LH-active gonadotropin at this stage may induce, in addition to multiple ovulations, the ovarian hyperstimulation syndrome (OHSS). This warning is particularly important with respect to patients with polycystic ovary syndrome (PCOS). Clinical symptoms of mild ovarian hyperstimulation syndrome are gastro-intestinal problems (abdominal pain, nausea, diarrhoea), painful breasts and mild to moderate enlargement of ovaries and ovarian cysts. Transient liver function test abnormalities suggesting hepatic dysfunction, which may be accompanied by morphologic changes in liver biopsies, have been reported in connection with OHSS. In rare cases severe ovarian hyperstimulation syndrome occurs, which may be life-threatening. This is characterized by large ovarian cysts (prone to rupture), ascites, often hydrothorax and weight gain, and occasionally thrombo-embolic phenomena.</p><p style="margin-left:49.65pt; margin-right:0in; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Women with generally recognised risk factors for thrombosis, such as a personal or family history, obesity (Body Mass Index &gt; 30 kg/m<sup>2</sup>) or thrombophilia, may have an increased risk of venous or arterial thromboembolic events, during or following treatment with gonadotropins. In these women the benefits of treatment with gonadotropins need to be weighed against the risks. It should be noted, however, that pregnancy itself also carries an increased risk of thrombosis.</p><p style="margin-left:49.65pt; margin-right:-.05pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Until 10 days after administration, Pregnyl may interfere with an hCG pregnancy test, leading to a false-positive pregnancy test.</p><p style="margin-left:49.65pt; margin-right:0in; text-align:left; text-indent:-21.3pt">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in; text-align:left; text-indent:-21.3pt">Additionally for males:</p><p style="margin-left:49.65pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;&nbsp;&nbsp;&nbsp;The formation of antibodies against hCG after administration of hCG has been described in the literature. In rare cases, this can result in ineffective treatment in males.</p><p style="margin-left:49.6pt; margin-right:0in; text-indent:-21.25pt">&nbsp;</p><p style="margin-left:49.65pt; text-align:left; text-indent:-21.3pt">Treatment with hCG leads to increased androgen production. Therefore:</p><p style="margin-left:49.65pt; text-align:left; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be kept under close medical supervision, since aggravation or recurrence may occasionally be induced as a result of increased androgen production.</p><p style="margin-left:49.6pt; text-indent:-21.25pt"><em>&nbsp;</em></p><p style="margin-left:49.6pt; text-indent:-21.25pt"><em>Male pediatric patients</em>:</p><p style="margin-left:49.6pt; text-align:left; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->hCG should be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development. Skeletal maturation should be monitored regularly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Interaction&nbsp;with&nbsp;other&nbsp;medicinal&nbsp;products and&nbsp;other&nbsp;forms&nbsp;of&nbsp;interaction</strong></p><p style="margin-left:28.35pt; text-align:left">No interaction studies have been carried out in the adult and pediatric population. Therefore, interactions with other commonly used medicines cannot be excluded.</p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>Fertility, pregnancy&nbsp;and&nbsp;lactation</strong></p><p style="margin-left:28.35pt; margin-right:0in"><em>Fertility</em></p><p style="margin-left:28.35pt; text-align:left">Pregnyl can promote fertility.</p><p style="margin-left:28.35pt; text-align:left">Pregnyl is used for the treatment of women undergoing ovarian induction or controlled ovarian hyperstimulation in assisted reproduction programs. In males, Pregnyl is used in the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.</p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in"><em>Pregnancy</em></p><p style="margin-left:28.35pt; margin-right:0in">Pregnyl is not indicated for use during pregnancy. There are no data on the use of chorionic gonadotropin during human pregnancy. Animal studies have shown reproduction toxicity as a result of hCG use (see section 5.3). The possible risk for humans is unknown. Pregnyl can be used at the beginning of pregnancy for luteal phase support, but should not be used at later stages of pregnancy.</p><p style="margin-left:28.35pt; margin-right:0in"><em>&nbsp;</em></p><p style="margin-left:28.35pt; margin-right:0in"><em>Lactation</em></p><p style="margin-left:28.35pt; margin-right:0in">There is no information available from clinical or animal studies on the excretion of hCG in milk. It is unlikely that hCG is excreted in human milk due to its high molecular weight. If hCG were to be excreted in human milk, it would be degraded in the gastrointestinal tract of the child.</p><p style="margin-left:28.35pt; margin-right:0in">The use of Pregnyl during lactation may be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>Effects&nbsp;on&nbsp;ability&nbsp;to&nbsp;drive&nbsp;and&nbsp;use&nbsp;machines</strong></p><p style="margin-left:28.35pt; text-align:left">As far as is known, this medicine has no influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>Undesirable&nbsp;effects</strong></p><p style="margin-left:28.35pt; text-align:left">Intramuscular or subcutaneous administration of Pregnyl may lead to local reactions at the site of injection. The majority of these local reactions are mild and transient in nature. Generalised hypersensitivity reactions have been observed rarely. Unwanted ovarian hyperstimulation syndrome (OHSS) is a potential serious side effect of Pregnyl.</p><p style="margin-left:28.35pt; text-align:left">&nbsp;</p><p style="margin-left:28.35pt; text-align:left">Drug-related adverse events are listed below by body/organ system and frequency. The frequencies are defined as follows: very common (&gt;1/10), common (&gt;1/100, &lt;1/10); uncommon (&gt;1/1000, &lt;1/100); rare (&gt;1/10,000, &lt;1/1000); and very rare (&lt;1/10,000).</p><p style="margin-left:28.35pt; text-align:left">&nbsp;</p><p style="margin-left:28.35pt"><u>Immune system disorders</u></p><p style="margin-left:28.35pt; text-align:left">Rare: generalized hypersensitivity reactions (e.g. generalized rash or fever).</p><p style="margin-left:28.35pt"><strong>&nbsp;</strong></p><p style="margin-left:28.35pt"><u>General disorders and administration site conditions </u></p><p style="margin-left:28.35pt; text-align:left">Rare: allergic reactions at the injection site (pain and/or rash).</p><p style="margin-left:28.35pt; text-align:left">Unknown frequency: local reactions at the site of injection (bruising, pain, redness, swelling or itching).</p><p style="margin-left:28.35pt; text-align:left">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in"><strong>In the female:</strong></p><p style="margin-left:28.35pt; margin-right:0in"><u>Blood vessel disorders</u></p><p style="margin-left:28.35pt">Rare: thromboembolism associated with FSH/hCG therapy, generally associated with severe OHSS.</p><p style="margin-left:28.35pt">&nbsp;</p><p style="margin-left:28.35pt"><u>Respiratory, thoracic and mediastinal disorders</u></p><p style="margin-left:28.35pt">Unknown frequency: hydrothorax as a sign of severe OHSS.</p><p style="margin-left:28.35pt">&nbsp;</p><p style="margin-left:28.35pt"><u>Gastrointestinal disorders</u></p><p style="margin-left:28.35pt; text-align:left">Common: abdominal and stomach disorders (such as nausea and diarrhea) as symptoms of mild OHSS.</p><p style="margin-left:28.35pt">Unknown frequency: ascites as a complication of severe OHSS.</p><p style="margin-left:28.35pt">&nbsp;</p><p style="margin-left:28.35pt"><u>Reproductive system and breast disorders</u></p><p style="margin-left:28.35pt; margin-right:0in">Unwanted ovarian hyperstimulation, mild (common) to severe (rare) ovarian hyperstimulation syndrome (OHSS, see section 4.4):</p><p style="margin-left:28.35pt">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in">Mild OHSS :&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful breasts</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:78.0pt">Mild to moderate enlargement of ovaries</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:78.0pt">Ovarian cysts</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:78.0pt">Abdominal pain</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:78.0pt">Abdominal discomfort</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:78.0pt">Gastrointestinal symptoms such as nausea, diarrhea and bloating.</p><p style="margin-left:28.35pt; margin-right:0in">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in">Severe OHSS: &nbsp;Large ovarian cysts (prone to rupture)</p><p style="margin-left:106.35pt; margin-right:0in">Acute abdominal pain</p><p style="margin-left:106.35pt; margin-right:0in">Ascites</p><p style="margin-left:106.35pt; margin-right:0in">Weight gain</p><p style="margin-left:106.35pt">Hydrothorax</p><p style="margin-left:106.35pt; text-align:left">In rare instances, thromboembolism has been associated with FSH/hCG therapy.</p><p style="margin-left:28.35pt">Not all symptoms described are always associated with OHSS.</p><p style="margin-left:106.35pt; margin-right:0in; text-indent:-78.0pt">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in"><u>Investigations</u></p><p style="margin-left:28.35pt; margin-right:0in">Unknown frequency: weight increase as a sign of severe OHSS.</p><p style="margin-left:28.35pt">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in"><strong>In the male:</strong></p><p style="margin-left:28.35pt; text-align:left"><u>Metabolism and nutrition disorders</u></p><p style="margin-left:28.35pt; text-align:left">Uncommon: water and sodium retention after administration of high dosages; this is regarded as a result of excessive androgen production.</p><p style="margin-left:28.35pt; text-align:left">&nbsp;</p><p style="margin-left:28.35pt"><u>Reproductive system and breast disorders</u></p><p style="margin-left:28.35pt; text-align:left">Rare: hCG treatment may cause gynecomastia.</p><p style="margin-left:28.35pt; text-align:left">&nbsp;</p><p style="margin-right:27.6pt"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To report any side effect(s):</strong></p><p style="margin-left:45.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Saudi Arabia: </u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p style="margin-left:45.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p><p style="margin-left:28.35pt; text-align:left">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-align:left">The acute toxicity of urinary gonadotropin preparations has been shown to be very low. Nevertheless there is a chance that too high a hCG dose may cause ovarian hyperstimulation syndrome (OHSS, see section 4.4).</p><p style="text-align:left">&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic&nbsp;properties</strong></p><p style="margin-left:28.35pt; text-align:left">Pharmacotherapeutic group: gonadotropins; ATC code G03G A01.</p><p style="margin-left:28.35pt; text-align:left">Pregnyl contains hCG, which has LH activity. LH is indispensible for normal female and male gamete growth and maturation and gonadal steroid production.</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left">In the female:</p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">Pregnyl is given as a substitute for the endogenous mid-cycle LH surge to induce the final phase of follicular maturation, leading to ovulation. Pregnyl is also given as a substitute for endogenous LH during the luteal phase.</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left">In the male:</p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">Pregnyl is given to stimulate Leydig cells to promote the production of testosterone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>Pharmacokinetic&nbsp;properties</strong></p><p style="margin-left:28.35pt; margin-right:0in"><u>Absorption and distribution</u></p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">Maximal hCG plasma levels after a single IM or SC injection will be reached after approximately 6 and 16 hours, respectively, in males, and in females in both cases after approximately 20 hours. Although high intersubject variability was observed, the difference related to gender after IM injection may be caused by gluteal fat thickness in women which exceeds that in men.</p><p style="margin-left:28.35pt; margin-right:0in"><u>Biotransformation</u></p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">HCG is metabolized for approximately 80 per cent, predominantly in the kidneys.</p><p style="margin-left:28.35pt; margin-right:0in"><u>Elimination</u></p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">IM and SC administration of hCG were found to be bioequivalent with regard to the extent of absorption and the apparent elimination half-life of approximately 33 hours. Based on the recommended dose regimens and elimination half-life, cumulation is not expected to occur.</p><p style="text-align:left">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>Preclinical&nbsp;safety&nbsp;data</strong></p><p style="margin-left:28.35pt; text-align:left">Safety pharmacology, repeated dose toxicity and genotoxicity studies do not indicate a special risk for humans. HCG has been shown to induce embryonic and fetal toxicity in mice.</p><p style="margin-left:28.35pt; text-align:left; text-indent:-28.35pt"><strong>&nbsp;</strong></p><p style="margin-left:28.35pt; text-align:left; text-indent:-28.35pt"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; List&nbsp;of&nbsp;excipients</strong></p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">The powder for injection contains mannitol, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate anhydrous and sodium carboxymethylcellulose.<br />The ampoule with the solvent contains sodium chloride (9 mg) and water for injections (1&nbsp;ml).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>Incompatibilities</strong></p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life
3 years.
Pregnyl may be used until the expiration date indicated on the package.
Since an opened ampoule cannot be stored in such a way to further guarantee the sterility of the contents, the solution should be used immediately after reconstitution.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>Special&nbsp;precautions&nbsp;for&nbsp;storage</strong></p><p style="margin-left:28.35pt; margin-right:-.05pt">Store at 2-15&deg;C, Store in the original package, in order to protect from light. Don&rsquo;t Freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>Nature&nbsp;and&nbsp;contents&nbsp;of&nbsp;container</strong></p><p style="margin-left:28.35pt; text-align:left"><u>Pregnyl 1500</u></p><p style="margin-left:42.55pt; text-align:left; text-indent:-14.2pt">- &nbsp;&nbsp; One pack contains 3, 6 or 10 ampoules of 2 ml with powder for injection corresponding to 1500 I.U. hCG and 3, 6 or 10 ampoules, respectively, each containing 1 ml solvent.</p><p style="margin-left:28.35pt; text-align:left">&nbsp;</p><p style="margin-left:28.35pt; text-align:left"><u>Pregnyl 5000</u></p><p style="margin-left:42.55pt; text-align:left; text-indent:-14.2pt">- &nbsp;&nbsp; One pack contains 1, 3 or 10 ampoules of 2 ml with powder for injection corresponding to 5000 I.U. hCG and 1, 3 or 10 ampoules, respectively, each containing 1 ml solvent.</p><p style="margin-left:28.35pt; text-align:left">&nbsp;</p><p style="margin-left:28.35pt; text-align:left">Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><strong>Special precautions for disposal and other handling</strong></p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">The powder for injection is reconstituted by adding the solvent (Pregnyl 1500 I.U. solution).</p><p style="margin-left:28.35pt; text-align:left">Pediatric dilution:</p><p style="margin-left:56.7pt; text-align:left; text-indent:-28.35pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take an empty sterile vial</p><p style="margin-left:56.7pt; text-align:left; text-indent:-28.35pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; add the 1 ml Pregnyl 1500 I.U. solution</p><p style="margin-left:56.7pt; text-align:left; text-indent:-28.35pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; add 2 ml sterile 0.9% NaCl solution</p><p style="margin-left:56.7pt; text-align:left; text-indent:-28.35pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gently swirl until the contents have mixed</p><p style="margin-left:56.7pt; text-align:left; text-indent:-28.35pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take 0.5 ml solution for the injection of 250 I.U. or 1 ml solution for the injection of 500&nbsp;I.U. and use the diluted Pregnyl solution immediately</p><p style="margin-left:56.7pt; text-align:left; text-indent:-28.35pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discard the remaining diluted Pregnyl solution.</p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">&nbsp;</p><p style="margin-left:28.35pt; margin-right:-.05pt; text-align:left">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                N.V. Organon
Kloosterstraat 6
5349 AB Oss, The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Last partial revision concerns sections: 2, 3, 4.1-4.6, 4.8 and 5.3: 29 October 2012. 


            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>